Advanced Enzyme Technologies Ltd
NSE:ADVENZYMES
Intrinsic Value
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. [ Read More ]
The intrinsic value of one
ADVENZYMES
stock under the Base Case scenario is
296.45
INR.
Compared to the current market price of 362.3 INR,
Advanced Enzyme Technologies Ltd
is
Overvalued by 18%.
Advanced Enzyme Technologies Ltd's market capitalization is 40.5B INR.
ADVENZYMES stock price is 362.3 INR.
ADVENZYMES stock (296.45 INR) is 18% less than its price (362.3 INR).
ADVENZYMES stock (250.54 INR) is 31% less than its price (362.3 INR). Open DCF Valuation
ADVENZYMES stock (342.36 INR) is 6% less than its price (362.3 INR). Open Relative Valuation
ADVENZYMES has upside potential of 13% compared to the average analyst price target.
Open Wall St Estimates
ADVENZYMES's ROE (Return on Equity) for the past 12 months is positive and is equal to 11%.
ADVENZYMES's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 12%.
ADVENZYMES has positive three-year average ROE (Return on Equity): 12%. The company is efficient at transforming stockholders' equity into net income.
ADVENZYMES's Revenue has grown by 13% over the past 12 months.
ADVENZYMES's ROE (Return on Equity) has decreased in the last 3 years from 16% to 11%.
ADVENZYMES's ROIC (Return on Invested Capital) has decreased in the last 3 years from 19% to 12%.
ADVENZYMES's Revenue has been growing by 8% per year for the last 3 years.
ADVENZYMES has positive three-year average ROIC (Return on Invested Capital): 14%. The company is efficient at using invested capital to generate operating income.
ADVENZYMES's Revenue is forecast to grow at a rate of 16% per year over the next 3 years.
ADVENZYMES has positive Net Income for the last twelve months.
ADVENZYMES has positive Operating Income for the last twelve months.
ADVENZYMES has positive Free Cash Flow for the last twelve months.
ADVENZYMES has positive Gross Profit for the last twelve months.
ADVENZYMES's D/E (Debt to Equity) is very low and is equal to 0.02.
ADVENZYMES's short-term assets (7B INR) exceed its short-term liabilties (874m INR).
ADVENZYMES's long-term assets (14B INR) exceed its long-term liabilties (2B INR).
ADVENZYMES has negative Net Debt. This means that the company has more cash and short-term investments (5B INR) than debt (215m INR).
ADVENZYMES's Altman Z-Score is very high and is equal to 14.98.
ADVENZYMES earns more than enough operating income (2B INR) to safely cover interest payments on its debt (26m INR).
Valuation Backtest
Advanced Enzyme Technologies Ltd
Run backtest to discover the historical profit from buying and selling
ADVENZYMES
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
This note will be permanently deleted.
Advanced Enzyme Technologies Ltd
Balance Sheet Decomposition
Advanced Enzyme Technologies Ltd
| Current Assets | 7.4B |
| Cash & Short-Term Investments | 4.7B |
| Receivables | 1.1B |
| Other Current Assets | 1.5B |
| Non-Current Assets | 7.1B |
| Long-Term Investments | 46.8m |
| PP&E | 2.9B |
| Intangibles | 3.8B |
| Other Non-Current Assets | 324.8m |
| Current Liabilities | 874m |
| Accounts Payable | 262.9m |
| Other Current Liabilities | 611.1m |
| Non-Current Liabilities | 1.1B |
| Long-Term Debt | 214.8m |
| Other Non-Current Liabilities | 867.6m |
Earnings Waterfall
Advanced Enzyme Technologies Ltd
|
Revenue
|
6B
INR
|
|
Cost of Revenue
|
-1.4B
INR
|
|
Gross Profit
|
4.6B
INR
|
|
Operating Expenses
|
-3.1B
INR
|
|
Operating Income
|
1.5B
INR
|
|
Other Expenses
|
-176.4m
INR
|
|
Net Income
|
1.4B
INR
|
Free Cash Flow Analysis
Advanced Enzyme Technologies Ltd
| INR | |
| Free Cash Flow | INR |
ADVENZYMES Profitability Score
Profitability Due Diligence
Advanced Enzyme Technologies Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
Score
Advanced Enzyme Technologies Ltd's profitability score is 62/100. The higher the profitability score, the more profitable the company is.
ADVENZYMES Solvency Score
Solvency Due Diligence
Advanced Enzyme Technologies Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Advanced Enzyme Technologies Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADVENZYMES Price Targets Summary
Advanced Enzyme Technologies Ltd
According to Wall Street analysts, the average 1-year price target for
ADVENZYMES
is 408 INR
with a low forecast of 404 INR and a high forecast of 420 INR.
Shareholder Return
ADVENZYMES Price
Advanced Enzyme Technologies Ltd
| Average Annual Return | 17.15% |
| Standard Deviation of Annual Returns | 59.47% |
| Max Drawdown | -55% |
| Market Capitalization | 40.7B INR |
| Shares Outstanding | 111 824 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Advanced Enzyme Technologies Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra and currently employs 322 full-time employees. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather and bio-fuels. Its oils and fats processing include oil extraction, oil refining fish oil processing, biodiesel and oleochemicals.
Contact
IPO
Employees
Officers
The intrinsic value of one
ADVENZYMES
stock under the Base Case scenario is
296.45
INR.
Compared to the current market price of 362.3 INR,
Advanced Enzyme Technologies Ltd
is
Overvalued by 18%.
You don't have any saved screeners yet
